Atantares

Cambridge, United States Founded: 2020 • Age: 6 yrs
Developer of precision medicines smart diagnostic devices by fusing biochip and AI technologies

About Atantares

Atantares is a Healthcare company based in Cambridge (United States) founded in 2020 by Xin Zhao, Aniruddh Sarkar, and Kumaran Kolandaivelu. Atantares has raised $13.99 million across 3 funding rounds from investors including Qiming Venture Partners, Alibaba Health and Frees Fund. Its chief executive, as recorded, is Xin Zhao. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Coagulopathies. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.

Company details

Developer of precision medicines smart diagnostic devices by fusing biochip and AI technologies. The company has developed a coagulation device that helps in monitoring specific drugs or blood products. It uses coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform. It provides a chimeric antigen receptor that helps in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. It uses an ultrasensitive immunoassay platform that provides cytokine profile data for managing CAR T-cell therapy and CRS mitigation.

  • Headquarters Cambridge, United States
  • Founders Xin Zhao, Aniruddh Sarkar, Kumaran Kolandaivelu
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website atantares.com
  • Social LinkedIn
Key Metrics
  • Total Equity Funding
    $13.99M (USD)

    in 3 rounds

  • Latest Funding Round
    $13.99M (USD), Seed

    Jul 2023

  • Investors

Funding Insights of Atantares

Atantares has successfully raised a total of $13.99M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $13.99 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $13.99M
  • Total Rounds 3
  • Last Round Seed β€” $13.99M
  • First Round $150,000

    (Feb 2020)

  • Investors Count 7

All 3 funding rounds of Atantares with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2023$13.99MSeed–Asia Green Fund
Jul 2020$449,968Grant––
Feb 2020$150,000Grant––
Valuation history

7 investors in total: 7 institutional.

Investors in Atantares

Atantares has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiming Venture Partners, Alibaba Health and Frees Fund.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Tech focused VC firm investing in early stage companies in the US & China
freesvc.comBeijing, China
Venture capital investments are directed toward multiple sectors.
2006qimingvc.comShanghai, China
asiagreenfund.com
Investment fund focused on biopharmaceutical innovation and growth.
2020fosunhealthcapital.comShanghai, China
jiachengcap.com
Online platform for pharmacy, consultations, and appointments is operated.
1998alihealth.cnBeijing, China
A government-backed foundation providing seed-stage investments to support small businesses.
1950nsf.govArlington, United States
Premium access

Investor details for Atantares

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Atantares

4 people are tracked at Atantares (4 in leadership).

NameRoleGroup
Xin Zhao
Founder & CEOLeadership
Aniruddh Sarkar
Co-FounderLeadership
Kumaran Kolandaivelu
Co-FounderLeadership
Dan Wu
Chief Technology OfficerLeadership
Premium access

Complete people profiles for Atantares

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Atantares

3 dated milestones of Atantares across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Atantares is founded.
  2. Funding First funding round of $150K.
  3. Funding Latest funding round, Seed, of $14.0M.

Competitors of Atantares

Atantares has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
guardanthealth.com2012Redwood, United States$557.5M1,351
Digital sequencing technology for cancer detection is developed.
foundationmedicine.com2010Cambridge, United States$96.5M1,707
Genomics-based diagnostic tests for cancer are provided.
archerdx.com2013Boulder, United States$152.6M429
Molecular cancer diagnostic products are developed using patented AMP technology.
Premium access

Detailed competitors of Atantares

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Atantares (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Atantares

Premium access

Complete news archive for Atantares

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Atantares

Atantares was founded in 2020.

Atantares is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Xin Zhao is the CEO of Atantares, as recorded in our data. They have also founded this company.

Atantares is a funded company, having raised a total of $13.99M across 3 funding rounds to date. The company's 1st funding round was a Grant of $150K, raised on Feb 2020.

Developer of precision medicines smart diagnostic devices by fusing biochip and AI technologies. The company has developed a coagulation device that helps in monitoring specific drugs or blood products. It uses coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform. It provides a chimeric antigen receptor that helps in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. It uses an ultrasensitive immunoassay platform that provides cytokine profile data for managing CAR T-cell therapy and CRS mitigation.

Atantares's top competitors include Guardant Health, Foundation Medicine and ArcherDX.

Atantares has 7 investors. Key investors include Qiming Venture Partners, Alibaba Health, Frees Fund, Asia Green Fund, and Fosun Health Capital.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available